1. J Int AIDS Soc. 2018 Mar;21(3):e25032. doi: 10.1002/jia2.25032.

Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey 
of treatment-naive individuals.

Arruda MB(1), Boullosa LT(1), Cardoso CC(1), da Costa CM(2), Alves CR(3), de 
Lima ST(4), Kaminski HT(5), Aleixo AW(6), Esposito AO(7), Cavalcanti AM(8), 
Riedel M(9), Couto-Fernandez JC(10), Ferreira SB(11), de Oliveira IC(12), Portal 
LE(13), Wolf HH(14), Fernandes SB(15), de M C Pardini MI(16), Feiteiro MV(17), 
Tolentino FM(18), Diaz RS(19), Lopes GI(20), Francisco RB(21), Véras NM(21), 
Pires AF(21)(22), Franchini M(21), Mesquita F(23), Tanuri A(1); HIV-BResNet.

Collaborators: de Melo Xavier Shimizu A, Jorge CRMP, Mello LMS, de Freitas EG, 
Tupinambás U, de Barros Rosa Costa DC, da Silva SP, da Graça Winhescki M, de 
Jesus CS, Dos Santos Nascimento ÉR, de Oliveira Prazim FE, da Rosa MTM, Salvador 
K, de Alcântara Belettini SA, Grotto RMT, de Oliveira PH, Gomes ÉVR, Dias DA, 
Galinskas J, Campos NC, Neto JBA.

Author information:
(1)Laboratório de Virologia Molecular, Departamento de Genética-IB, Universidade 
Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
(2)Fundação de Medicina Tropical do Amazonas, Manaus, AM, Brazil.
(3)Laboratório de Pesquisa, LAPI Universidade Federal da Bahia, Hospital 
Universitário "Prof. Edgar Santos", Salvador, BA, Brazil.
(4)Laboratório Central de Saúde Pública do Ceará (Lacen-CE), Fortaleza, CE, 
Brazil.
(5)Laboratório Central de Saúde Pública do Distrito Federal, Setor de Grandes 
Areas Norte (SGAN) 601, Brasilia, DF, Brazil.
(6)Faculdade de Medicina, Laboratório de Imunologia e Biologia Molecular (DIP), 
Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
(7)Laboratório Central de Saúde Pública de Mato Grosso do Sul, Campo Grande, MS, 
Brazil.
(8)Laboratório Central de Saúde Pública de Pernambuco, Recife, PE, Brazil.
(9)Laboratório Municipal de Curitiba, Curitiba, PR, Brazil.
(10)Laboratório de AIDS e Imunologia Molecular, Departamento de Imunologia, 
FIOCRUZ, Rio de Janeiro, RJ, Brazil.
(11)UFRJ, Laboratório de Carga Viral, Hospital Universitário Clementino Fraga 
Filho, Rio de Janeiro, RJ, Brazil.
(12)Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brazil.
(13)Laboratório Central de Saúde Pública do Rio Grande do Sul, Porto Algre, RS, 
Brazil.
(14)Laboratório do Hospital Nossa Senhora da Conceição, Porto Alegre, RS, 
Brazil.
(15)Laboratório Central de Saúde Pública de Santa Catarina, Florianópolis, SC, 
Brazil.
(16)Laboratório de Biologia Molecular do Hemocentro de Botucatu, Faculdade de 
Medicina, UNESP, Botucatu, SP, Brazil.
(17)Laboratório de Pesquisa em AIDS-Hospital de Clíncas da UNICAMP, Campinas, 
SP, Brazil.
(18)Laboratório de Biologia Molecular-Instituto Adolfo Lutz de São José do Rio 
Preto, São José do Rio Preto, SP, Brazil.
(19)Escola Paulista de Medicina, Laboratório de Retrovirologia, Universidade 
Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
(20)Laboratório de Retrovírus, Núcleo de Doenças Sanguíneas e Sexuais, Centro de 
Virologia, Instituto Adolfo Lutz Central, São Paulo, SP, Brazil.
(21)Departamento de Vigilância, Prevenção e Controle das DST, AIDS e Hepatites, 
Setor Administrativo Federal Sul (SAFS) 02, Secretaria de Vigilância em Saúde, 
Ministério da Saúde, Brasília, DF, Brazil.
(22)Programa de Pós Graduação em Saúde Coletiva, Faculdade de Medicina, 
Faculdade de Ciências de Saúde, Universidade de Brasília, Brasília, DF, Brazil.
(23)Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

INTRODUCTION: In Brazil, more than 487,450 individuals are currently undergoing 
antiretroviral treatment. In order to monitor the transmission of drug-resistant 
strains and HIV subtype distribution in the country, this work aimed to estimate 
its prevalence and to characterize the nationwide pretreatment drug resistance 
in individuals recently diagnosed with HIV between 2013 and 2015.
METHODS: The HIV threshold survey methodology (HIV-THS, WHO) targeting 
antiretroviral-naive individuals with recent HIV diagnosis was utilized, and 
subjects were selected from 51 highly populated cities in all five Brazilian 
macroregions. The HIV pol genotypic test was performed by genomic sequencing.
RESULTS: We analysed samples from 1568 antiretroviral-naive individuals recently 
diagnosed with HIV, and the overall transmitted drug resistance (TDR) prevalence 
was 9.5% (150 sequences). The regional prevalence of resistance according to 
Brazilian geographical regions was 9.4% in the northeast, 11.2% in the 
southeast, 6.8% in the central region, 10.2% in the north and 8.8% in the south. 
The inhibitor-specific TDR prevalence was 3.6% for nucleoside reverse 
transcriptase inhibitors (NRTIs), 5.8% for non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) and 1.6% for protease inhibitors (PIs); 1.0% of individuals 
presented resistance to more than one class of inhibitors. Overall, subtype B 
was more prevalent in every region except for the southern, where subtype C 
prevails.
CONCLUSIONS: To the best of our knowledge, this is the first TDR study conducted 
in Brazil with nationwide representative sampling. The TDR prevalence revealed a 
moderate rate in the five Brazilian geographical regions, although some cities 
presented higher TDR prevalence rates, reaching 14% in São Paulo, for example. 
These results further illustrate the importance of surveillance studies for 
designing future strategies in primary antiretroviral therapy, aiming to 
mitigate TDR, as well as for predicting future trends in other regions of the 
globe where mass antiretroviral (ARV) treatment was implemented.

© 2018 The Authors. Journal of the International AIDS Society published by John 
Wiley & sons Ltd on behalf of the International AIDS Society.

DOI: 10.1002/jia2.25032
PMCID: PMC5835841
PMID: 29504269 [Indexed for MEDLINE]